Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disease affecting approximately 1 in 6,000 people, and represents one of the most common genetic causes of epilepsy.
Epilepsy affects 90% of the patients and appears in the first 2 years of life in the majority of them. Early onset of epilepsy in the first 12 months of life is associated with high risk of cognitive decline and neuropsychiatric problems including autism.
Prenatal or early infantile diagnosis of TSC, before the onset of epilepsy, provides a unique opportunity to monitor EEG before the onset of clinical seizures, thus enabling early intervention in the process of epileptogenesis.
In this review, we discuss the current status of knowledge on epileptogenesis in TSC, and present recommendations of American and European experts in the field of epilepsy. The most frequently affected organs are the brain, kidneys, heart, liver, and lungs, although other organs (i.e., pancreas, spleen, and thyroid gland) may show signs of TSC as well. Recent studies indicate that the incidence of TSC is at least 1 in 6,000 live births. However, the true incidence seems to be underestimated, as some mosaic patients may be difficult to diagnose (Jozwiak, Domanska-Pakieła, Kwiatkowski, & Kotulska, 2005) . Molecular studies have identified two genes that are responsible for the manifestations of TSC: TSC1 (on chromosome 9q34) and TSC2 (on chromosome 16p13).
In addition to the typical lesions of TSC represented by hamartomas, neurologic issues represent one of the most important clinical problems. They consist of high risk of seizures, intellectual disability (ID), autism spectrum disorder (ASD), and other behavioral disorders (Henske, Jóźwiak, Kingswood, Sampson, & Thiele, 2016) , and appear in 85-90% of the patients with this condition. Among them, epilepsy is the most common symptom, present in 80-90% of the patients and appearing mainly in the first 2 years of life. Seizure control is therefore a critical issue in the clinical management of individuals with TSC.
The importance of epilepsy and ID in TSC was already recognized by Vogt in 1908 in his first set of diagnostic criteria (Vogt's triad): epilepsy, ID (formerly referred to as mental retardation), and adenoma sebaceum (angiofibroma) (Vogt, 1908) . Recent years have brought significant progress in the diagnosis and treatment of epilepsy and its comorbidities in TSC. Animal studies demonstrating the efficacy of early or preventative treatment (Zeng, Xu, Gutmann, & Wong, 2008) , the increasing use of Electroencephalogram (EEG) as a biomarker of epileptogenesis (Doma nska-Pakieła et al., 2014) , the first clinical preventative trials in infants and children younger than 2 years of age (EPISTOP and PREVENT trials) , and the approval of mTOR inhibitors in the United States and in Europe as antiepileptic drugs (Curatolo et al., 2016) , are among the most important turning points in epilepsy treatment in TSC.
| PATHOGENESIS OF EPILEPSY IN TSC
Genetic mutations in either TSC1 or TSC2 lead to overactivity of the mammalian target of rapamycin (mTOR) pathway, an intracellular signaling pathway involved in cell growth and proliferation, protein synthesis, and metabolism (Curatolo, 2015) . mTOR is a serine/threonine kinase exerting its activity in response to nutrients and growth factors, and plays a significant role in the regulation of synaptogenesis, axonal polarization, and myelination (Curatolo, 2015) . mTORC1 signaling is activated early during brain development, and pathological neural networks with cellular, molecular, and functional abnormalities are already present in the prenatal period (Prabowo et al., 2013) . This early hyperactivation of mTOR might lead to abnormalities of migration and orientation of neural cells, leading to abnormal cortical lamination and dendritic arborization. The alteration of this crucial pathway also includes the disruption of GABAergic interneuron development as well as the regulation of the glutamatergic function via inotropic glutamate receptors. This corresponds to an imbalance between excitation and inhibition, which is an obvious predisposing factor to epileptic seizures (Curatolo, 2015) . From a neuropathologic point of view, the early dysregulation of the mTOR pathway, causing altered migration and cell morphology, leads to the formation of tubers including different abnormal cells, such as dysplastic neurons and giant cells. Tubers are the hallmark of TSC pathology, and can be already visible on fetal magnetic resonance imaging (MRI) during prenatal life. They are dynamic lesions, and changes within tubers, through pre-and postnatal life, may contribute to the establishment of extensive epileptogenic networks (Curatolo, Moavero, Van Scheppingen, & Aronica, 2018) . Tubers represent focal malformations of cortical development, and are characterized by loss of the hexalaminar cortical architecture, presence of an excessive number of astrocytes, and by dysmorphic neurons and giant cells . Although tubers are the most evident lesions, for which there is a documented link with epilepsy, many other structural and microstructural lesions are found in the TSC brains. In particular, mTOR alteration leads to focal dyslamination and isolated giant cells even in the absence of major structural abnormalities, resulting in global and focal network changes that may play a role in both epileptogenicity and abnormal neurodevelopment. White matter appears to be extensively involved too; in fact, white matter migration lines are seen in over one third of TSC patients at conventional brain MRI as a result of abnormal migration (Curatolo, Moavero, & De Vries, 2015) . However, also normal appearing white matter can be interested by microstructural changes that are visible when diffusion tensor imaging is performed, and can be linked to epileptogenesis (Widjaja et al., 2010) . Furthermore, white matter abnormalities appear to be more evident in children with early onset and refractory epilepsy with persistent seizures seeming to determine extensive connectivity alterations in areas of the brain that are crucial for language, social development, and global intellectual functioning (Moavero et al., 2016) .
| NATURAL COURSE OF EPILEPSY IN TSC
The first large studies addressing epilepsy in TSC reported generalized seizures-and specifically infantile spasms-as the most common type of initial seizures, appearing between the fourth and the sixth month of life (Gomez, 1988) . In recent years, prenatal diagnosis of TSC has been available in an increasing number of patients, resulting in the discovery of 5-6% of TSC patients with neonatal presentation of epilepsy, with the majority of them exhibiting large cortical dysplasias brain MRI . and tonic-clonic, myoclonic, or atonic seizures. In about 25-30% of the patients, especially those with a history of infantile spasms, epilepsy evolves into Lennox-Gastaut syndrome .
Of 248 TSC patients with epilepsy, 155 (62%) developed refractory epilepsy , which is two times higher the number of drug resistant epilepsy in the general population with epilepsy.
Similarly, Jeong, Nakagawa, and Wong (2017) in their large Natural History Database including 2,034 TSC patients, found a high incidence of drug-resistant epilepsy, reaching 59.6% in children with focal seizures.
| EVOLUTION OF EEG CHARACTERISTICS
Early diagnosis of TSC in infants, even before the onset of clinical seizures, is currently feasible (Słowi nska et al., 2018) . The regular EEG surveillance recommended for these infants has allowed to define the EEG features-mainly based on the distribution of interictal epileptiform discharges-and their intensity (Doma nska-Pakieła et al., 2014).
Both typical and variant hypsarrhythmia have been reported in children with TSC, while ictal EEG of epileptic spasms is often characterized by fast rhythms, often preceded by focal or multifocal spikes (Liu et al., 2012) .
Ictal patterns of recorded focal seizures include flattening or lowvoltage fast activity evolving into rhythmic theta activity or rhythmic theta-delta activity, and/or diphasic spike-wave discharges (Savini, Mingarelli, Vignoli, et al., 2018) . On the other hand, a characteristic interictal pattern is not recognized in TSC patients: focal or multifocal spikes, spike-and-wave complexes, sharp waves, and sharp and slow-wave complexes have been detected in the EEG of all TSC patients with epilepsy. Jansen, van Huffelen, Bourez-Swart, and van Nieuwenhuizen (2005) found that interictal activity is more frequently detected in the fronto-temporal regions, and this finding is potentially important in view of a surgical approach (Jansen et al., 2005) . At follow-up, in seizuresustained patients, the incidence of epileptiform discharges in the initial EEG recordings was higher (88.2%) than in the seizure-controlled group (55.5%). This result suggests that initial EEG abnormalities may be related to incurableness (Park, Lee, Son, Kim, & Woo, 2011) .
| EPILEPSY AND ITS IMPACT ON INTELLECTUAL DEVELOPMENT
About 50% of TSC patients exhibit ID, with an over-representation of severe to profound ID (Curatolo, Moavero, & De Vries, 2015) .
Cognitive impairment in TSC is thought to be a multifactorial condition (Jansen et al., 2008) . Studies in animal models have suggested a biological basis for cognitive and behavioral deficits associated with TSC, even in the absence of apparent cerebral lesions and seizures. mTOR dysregulation may be the underlying pathogenic mechanism (Goorden, van Woerden, van der Weerd, Cheadle, & Elgersma, 2007) .
Many studies report genotype, number of tubers, tuber/brain proportion, and epilepsy as risk factors for ID (Benova et al., in press; Gipson & Johnston, 2017; Kaczorowska et al., 2011) . With regard to epilepsy, patients with ID tend to have early onset seizures, take more antiepileptic drugs (AEDs), exhibit more seizure types and with a higher frequency (Wang et al., 2017) . It has been recently demonstrated that early onset seizures are associated with an increased risk of neurodevelopmental and cognitive problems, including ASD (Capal et al., 2017) . It is also known that the risk of ID increases significantly with prolonged duration of infantile spasms (IS), gap between seizures onset and the start of treatment, and poor control of subsequent seizures after IS.
Infants with spasms controlled with Vigabatrin (VGB) benefit from clear long term cognitive and behavioral improvement, even when focal seizures persist, suggesting that control of IS could be a key factor in cognitive outcome. Very early treatment after the onset of seizures, or even before, can positively influence the final cognitive outcome, even though not completely reversing cognitive impairment (Cusmai, Moavero, Bombardieri, Vigevano, & Curatolo, 2011) .
| CORRELATIONS OF EPILEPSY WITH GENETICS
TSC mouse models showing reduced expression of TSC1 exhibit aberrant neurons similar to those seen in TSC cortical tubers and present with early onset spontaneous seizures with EEG abnormalities, demonstrating that epilepsy in TSC is directly linked to mTOR hyperactivation (Meikle et al., 2007) .
Although TSC is characterized by wide clinical variability, genotype-phenotype correlations regarding epilepsy in humans have emerged. Patients with a pathogenic variant in TSC2 exhibit epilepsy more frequently than those with a pathogenic variant in TSC1, with a median frequency from the major studies of 81% (range 65-97%) and 75% (range 58-91%), respectively (Curatolo, Moavero, Roberto, & Graziola, 2015) . Individuals with a pathogenic variant in TSC2 also tend to present with seizures earlier than the other group, are more likely to develop focal seizures, complex partial seizures, and infantile spasms, whereas other types of seizures occur in equal frequency in the two groups (Kothare et al., 2014) . van Eeghen, Nellist, van Eeghen, and Thiele (2013) showed that certain but not all central TSC2 missense mutations (exons 23-33) are associated with a lower risk of infantile spasms compared to missense mutations in the proximal and terminal regions of the same gene.
Individuals with no mutation identified (NMI) exhibit epilepsy less frequently (range 56-68%) and, when they do, seizures tend to occur later in some of them compared to patients with a pathogenic variant in TSC2, but may be as difficult to control as in the individuals with a known mutation .
Despite emerging genotype-phenotype correlations, caution should be taken when counseling patients for risk of epilepsy based on the mutational status, as clinical variability and numerous exceptions are emerging.
| PRESEIZURE (PREVENTIVE) TREATMENT OF EPILEPSY
In recent years an increasing number of TSC patients is diagnosed prenatally or soon after birth, allowing subsequent clinical observations before epilepsy onset. Serial EEG follow-up of young infants with TSC is currently recommended by European (Curatolo et al., 2012) , American (Wu et al., 2016) , and Australian experts (Chung et al., 2017) .
In the majority of TSC infants, the first clinical seizures are noticeable at the age of 3-5 months. With a traditional approach to epilepsy treatment (treatment started as soon as clinical seizures appear) neurodevelopmental delay and drug-resistant epilepsy at the age of 24 months are observed in 48% and 42% of TSC children, depending on the studies Jóźwiak et al., 2011) .
It is now widely accepted that clinical seizures are preceded by a latent period of epileptogenesis (Pitkanen & Lukasiuk, 2011) Regular EEG surveillance with vEEG carried out every 4-6 weeks in infants with TSC enables early recognition of initial subtle focal seizures that are frequently overlooked by caregivers (Whitney et al., 2017) . Such approach and the early treatment of seizures reduce the risk of ID to 61%, as opposed to 100% in children receiving delayed treatment (Cusmai et al., 2011) . However, treatment introduced after the onset of clinical seizures is still associated with 32% of severe forms of Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) in the first 2 years of life (Cusmai et al., 2011) .
As shown in animal models, interventions applied prior to the onset of clinical epilepsy can prevent or delay the development of seizures (Zeng et al., 2008; Zhu et al., 2018) . The time between early diagnosis of TSC and seizure onset offers the ideal therapeutic window for preventative strategies in infants (Jozwiak & Kotulska, 2014 ).
An open, prospective study of 14 TSC infants demonstrated that antiepileptogenic treatment with Vigabatrin introduced before the onset of clinical or electroencephalographic seizures but after multifocal epileptiform discharges on EEG significantly reduces the risk of seizure development and ID . In this group, only 14% of the children developed infantile spasms, and there were no cases of severe ID at the age of 24 months. Moreover, drug resistant epilepsy was observed in 7% of these children versus 42% in children receiving Vigabatrin 7 days after the onset of clinical seizures . 
| POST-SEIZURE TREATMENT OF EPILEPSY
Despite recent advances in preventative treatment, treatment of existing epilepsy associated with TSC remains a major challenge. No consensus regarding the most effective AED has been reached yet, with the exception of Vigabatrin (VGB) for IS, representing the first-line therapy (Pellock et al., 2010) . Visual field constriction caused by VGB should be taken into consideration; however, the balance between positive and negative effects-catastrophic sequelae of infantile spasms against the good response to VGB-supports this treatment choice. In order to minimize side effects, some authors proposed a supplementation with taurine (Jammoul et al., 2009 ), but the efficacy of such approach has not been confirmed on long-term follow up yet.
In our experience, higher doses of VGB (100-150 mg/kg/day) are effective in children younger than 2 years. Treatment lasting longer than 6 months is now recommended, after Humphrey et al. (2006) reported that a 6-month treatment was effective, but seizures reap- Although not widely accepted, according to the European experts in TSC Vigabatrin is the recommended treatment also for focal seizures before age 1 year due to its high efficacy in this specific group of patients (Curatolo et al., 2012) . In order to control drop attacks and tonic seizures, especially in patients with Lennox-Gastaut Syndrome, Rufinamide should be considered as a useful option (Curatolo et al., 2012) . Clobazam has been noted to be safe and effective in treating refractory epilepsy in TSC (69% had >50% seizure reduction) (Jennesson, van (Franz et al., 2001) , and Levetiracetam (LEV, 40%
had >50% reduction in seizures) (Collins, Tudor, Leonard, Chuck, & Franz, 2006) .
With regard to seizure control, it has been reported that 35.6% of patients from a large group of 160 had their seizures controlled: by monotherapy in 56% and by polytherapy in 32% (Vignoli et al., 2013) .
The most effective AEDs appeared to be Carbamazepine (CBZ) and
Valproic acid (VPA) (Vignoli et al., 2013) . Overwater et al. (2015) used several different AEDs, such as VPA, LEV, and VGB, with VPA being the most frequently prescribed first treatment. This was also the most frequently used drug in infants presenting with focal seizures. Similar data have been obtained in a Swedish study where VPA, CBZ, LTG, LEV, and TPM were the most commonly prescribed drugs (Welin et al., 2017) . Recently, also Lacosamide appeared to be an effective and safe treatment of refractory focal onset seizures in TSC (Geffrey, Belt, Paolini, & Thiele, 2015) .
| SURGICAL TREATMENT
Surgical therapy for epilepsy in TSC was advocated as far back as 1966 (Perot, Weir, & Rasmussen, 1966) based on the hypothesis that a single tuber might well be responsible for epileptogenesis.
As in all epilepsies, surgery in TSC should be considered early in patients with drug resistant epilepsy (DRE) despite treatment with two AEDs (Kwan et al., 2010) . Non-invasive recordings together with MRI might be sufficiently informative when there is a clear anatomoelectroclinical correlation. Invasive recordings should be considered whenever the correlation between MRI and EEG data is not clear (Curatolo et al., 2012) .
The presence of multiple tubers, multiple interictal foci, bilateral seizures, or epileptic spasms (Chipaux et al., 2017) should not prevent from initiating presurgical evaluation, since a single epileptogenic tuber can be found responsible of the most impairing seizures (Curatolo et al., 2012) .
Risk factors associated with seizure recurrence after surgery are poorly understood, and we still need to learn when a tuber will become epileptogenic. Therefore, the perspective of future seizure recurrence should be weighted against that of a temporary relief of epilepsy during a critical period of neurodevelopment .
Controversy exists about the contribution of tubers, perituberal cortex and the underlying genetic abnormality to epileptogenesis. Kannan, Vogrin, Bailey, Maixner, and Harvey (2016) provided support for a central role of the tuberal core in seizure initiation and propagation. Other studies report that electrical activity (complete removal of areas with High Frequency Oscillations and fast ripple at ictal onset) is the most relevant data in order to obtain a good outcome, regardless of the MRI findings (Fujiwara et al., 2016) .
Some studies support the hypothesis that a greater extent of resection (i.e., more than just the tuber) is associated with a higher probability of seizure freedom (Fallah et al., 2015) , and that epileptogenic regions are mostly characterized by "Focal Cortical Dysplasia (FCD)-like" changes outside cortical tubers (Jahodova et al., 2014) . Therefore, FCD seems to be an important hallmark. Malformations of the cerebral cortex meeting the criteria for FCD type IIb were a frequent finding and an indication for early epilepsy surgery also in a series of patients with neonatal onset of epilepsy in TSC .
However, surgery in TSC is not always effective. Literature data report a highly variable rate of seizure freedom (25-90%) (Fallah et al., 2013; Jansen, van Huffelen, Algra, & van Nieuwenhuizen, 2007; Madhavan et al., 2007; Moavero, Cerminara, & Curatolo, 2010; Weiner et al., 2006; Wu et al., 2010) , but in general the literature suggests that resective surgery may be beneficial in a selected population of TSC patients with drug-resistant epilepsy. Individuals with the forme fruste have been reported to have an excellent surgical outcome (Teutonico et al., 2008) .
Finally, cost effectiveness is another parameter that should be kept in mind when evaluating possible surgery or other treatment options. For instance, Fallah, Wang, Lewis, Baca, and Mathern (2016) showed that resective epilepsy surgery resulted as the most costeffective treatment option in TSC children with DRE after the introduction of a third AED but before vagus nerve stimulation, and the authors concluded that the most cost-effective treatment should be chosen based on available resources.
Epilepsy surgery in TSC remains challenging and should be driven by a sound presurgical hypothesis based on MRI, Video-EEG recordings, and invasive recordings when needed, keeping in mind surgery goals.
| VAGUS NERVE STIMULATION
Vagus Nerve Stimulation (VNS) is a therapeutic option that should be taken into account when resective surgical intervention is not feasible in patients with drug resistant epilepsies (Marras et al., 2013) . Lagae et al. (2015) studied the efficacy of VNS therapy in a group of patients with highly drug-resistant childhood epilepsy: the only factors that made a difference in the outcome were age at implantation and duration of epilepsy. In the youngest group, 7/9 were responders (77%), including three of the four seizure-free patients: the three seizure-free children had TSC. In a retrospective series of 11 patients, Zamponi, Petrelli, Passamonti, Moavero, and Curatolo (2010) found that the patients who had received implantation during childhood exhibited a better improvement in cognitive and seizure outcome (significantly improved in 72% of the patients).
Major and Thiele (2008) performed a retrospective study of 16 adults and children with TSC and intractable epilepsy who received VNS, with a longer follow-up (average: 4 years). Eighty-two percent experienced at least a 50% reduction in seizure burden, and improved function was observed in five individuals (31%), but no patients resulted seizure free. In a series of 11 individuals with drug resistant epilepsy and TSC, Elliott et al. (2009) reported that nine of them (82%) experienced at least a 67% reduction in seizure burden. Finally, a cost-utility analysis found VNS implantation to be more expensive and less effective than alternative strategies, and suggested that it
should not be prioritized (Fallah et al., 2016 ).
In conclusion, literature data support the suggestion to use VNS only as a third line therapy (Curatolo et al., 2012) .
| KETOGENIC DIET
Ketogenic diet (KD) has been reported as effective in small series of TSC patients (Coppola et al., 2006; Kossoff, Thiele, Pfeifer, McGrogan, & Freeman, 2005; Larson, Pfeifer, & Thiele, 2012; Park et al., 2017) . Martinez, Pyzik, and Kossoff (2007) demonstrated that children with TSC are more likely to have seizure recurrence if KD is weaned, and that they may benefit from being on KD for longer than 2 years if seizure freedom has been achieved.
Hypotheses regarding the possible specific mechanism involved in seizure control with KD in TSC patients have been reported.
Tuberin is phosphorylated by AMP-activated kinase (AMPK) in response to certain stresses, such as energy starvation (Inoki, Zhu, & Guan, 2003) . KD may thus represent a form of cellular stress involving the AMPK pathway, as preclinical data (cited previously) show a change in the brain's energy state during the KD. Interestingly, inhibition of one component of this pathway with rapamycin prevents the development of epilepsy in mice harboring a TSC1 mutation (Zeng et al., 2008) . Whether the KD exerts a similar mechanism in this condition remains to be clarified (Hartman, 2008) . Based on the recent literature, KD should be considered in those patients with epilepsy that is difficult to treat (Kossoff et al., 2005; Park et al., 2017) .
| MARIJUANA DERIVATIVES
Cannabidiol (CBD) is one of the non-psychoactive components of the cannabis plant. In recent years, the use of CBD has been challenged in intractable epilepsy, especially in early onset epileptic encephalopathies.
However, the pharmacologic mechanisms have not been fully understood yet (Reddy & Golub, 2016) . Hess et al. (2016) have recently studied the efficacy, safety, and tolerability of CBD in patients with TSC and drugresistant epilepsy, finding that median reduction in seizure frequency was 48.8%, and approximately 50% of the patients demonstrated a >50% reduction in seizures. The response was maintained during the 12-month follow-up. These findings suggest that CBD is a potential antiseizure medication for intractable epilepsy in TSC, and randomized controlled trials are needed to confirm these data.
| EPILEPSY TREATMENT IN TSC WITH MTOR INHIBITORS
mTOR inhibitors (e.g., Everolimus and Sirolimus) are immunosuppressants that inhibit the mTOR kinase, which is hyperactivated in TSC patients.
Muncy, Butler, and Koenig (2009) reported for the first time on a 10-year-old girl treated with rapamycine for frequent seizures, who obtained good response. Subsequent larger studies exploring the beneficial role of mTOR inhibitors in epilepsy treatment in TSC came from the observation of patients treated with this medication because of growing subependymal giant cell astrocytomas (SEGAs) (Kotulska et al., 2013; Krueger et al., 2013; Perek-Polnik, Jozwiak, Jurkiewicz, Perek, & Kotulska, 2012) .
Experimental trails and clinical observations confirmed that inhibition of the mTOR pathway is an attractive therapeutic option, and that it may modify the process of epileptogenesis (Curatolo, 2015; Krueger et al., 2013; Sadowski, Kotulska-Jóźwiak, & Jóźwiak, 2015; Samueli et al., 2016; Stafstrom, Staedtke, & Comi, 2017) . The largest prospective, randomized, multicenter, placebo-controlled study aiming at assessing the effect of Everolimus on seizure frequency in TSC patients with drug-resistant epilepsy (EXIST-3) documented a positive antiepileptic effect of Everolimus as additional antiepileptic therapy with tolerable safety profile (French et al., 2016) . The reduction of ≥50% in seizure frequency was significantly higher in patients treated
with Everolimus compared to the placebo group. Furthermore, a positive effect of Everolimus was observed in a variety of seizure types (French et al., 2016) .
Recently, Krueger et al. (2016) reported the long-term results of their prospective, open-label, non-randomized study of Everolimus in drug-resistant epilepsy in TSC. The authors documented a sustained reduction in seizure frequency in the group of children <6 years . This effect has been confirmed in the long-term follow-up of the EXIST3 trial as well (Curatolo, Franz, Lawson, et al., 2018) . Everolimus plasma concentrations within a range of 5-7 ng/mL initially and 5-15 ng/mL in the event of an inadequate clinical response . Starting doses depend on age and concomitant use of CYP3A4/P-glycoprotein inducers/inhibitors.
| CONCLUSIONS AND FUTURE PERSPECTIVES
Despite significant improvements in understanding TSC, epilepsy treatment in individuals affected by this condition remains challenging. As 71% of the patients develop epilepsy in the first 24 months of life 
